In medical news:

The Food and Drug Administration (FDA) announced that it is investigating the risk of potentially harmful brain deposits in patients who are given repeated MRIs using imaging drugs that contain gadolinium, a heavy metal. The investigation is the result of new research that unexpectedly found gadolinium in the brain tissue of patients when the metal, used as a contrast agent to enhance imaging, is supposed to be eliminated totally from the bodies of healthy people by the kidneys. The agency has not released any plans to require label changes for the nine drugs on the market that currently contain gadolinium, but they have issued guidance to physicians to “consider limiting” their use and to reexamine “the necessity of repetitive” MRIs involving contrast agents.

Read the FDA guidance here. Read a ProPublica report on the issue here.

Leave a Comment

Your email address will not be published. Required fields are marked *